Tesamorelin vs CJC-1295 Ipamorelin Price Comparison

A tesamorelin vs CJC-1295 ipamorelin price comparison has to answer a structural question before it answers a pricing one: is a single tesamorelin vial being priced against a single CJC-1295/ipamorelin blend vial, or against two separate vials bought together. Sellers list these three peptides in both forms, and mixing up which structure is being compared is the fastest way to reach a wrong conclusion about which option costs less. Once the listing structure is confirmed, the comparison still has to be normalized to cost per mg before the sticker prices mean anything.

Two Different Listing Structures

Tesamorelin is almost always sold as a single-compound vial with one mg figure printed on the label. CJC-1295 and ipamorelin, by contrast, are frequently sold together as a pre-mixed blend vial, where the label lists a combined mg total split between the two peptides, alongside separate single-compound listings for each.

That distinction matters for a tesamorelin vs CJC-1295 ipamorelin price comparison because a blend vial’s total mg figure is not directly comparable to a tesamorelin vial’s mg figure. A 10 mg blend vial does not contain 10 mg of CJC-1295; it contains some split of CJC-1295 and ipamorelin that together total 10 mg, and the split is set by the seller, not by any fixed standard.

Reading a Blend Label Correctly

Before any price comparison happens, the blend label needs to specify the split, not just the total. A listing that states “CJC-1295/Ipamorelin blend, 10 mg” without a ratio leaves the buyer unable to calculate a per-compound cost at all — only a per-vial cost for the combined product.

Where a split is given, for example a 5 mg CJC-1295 / 5 mg ipamorelin blend, the per-compound mg figures can be pulled out and compared against a standalone tesamorelin listing the same way any two single compounds would be compared.

Worked Comparison

Consider three hypothetical listings, structured the way this category is typically sold:

Listing	Contents	Listed price	Cost per mg
Tesamorelin (hypothetical)	10 mg, single compound	$160	$16.00
CJC-1295/Ipamorelin blend (hypothetical)	5 mg CJC-1295 + 5 mg ipamorelin	$80	$8.00 per blended mg
Ipamorelin (hypothetical), standalone	5 mg, single compound	$40	$8.00

The tesamorelin figure is calculated the same way as in any single-compound comparison: $160 divided by 10 mg equals $16.00 per mg. Rechecking: 160 ÷ 10 is 16, confirmed.

The blend figure needs an extra step. $80 divided by the vial’s total 10 mg gives $8.00 per blended mg — but that number describes the combined product, not either compound individually. To isolate CJC-1295’s own cost, the blend price has to be attributed across the 5 mg of CJC-1295 in the vial, which assumes the seller priced both halves of the blend evenly. If $80 is treated as evenly split, 5 mg of CJC-1295 accounts for $40 of the vial, giving $40 ÷ 5 = $8.00 per mg for CJC-1295 specifically, and the same $8.00 per mg for the ipamorelin half. Rechecking: 40 ÷ 5 is 8, confirmed, and the even split assumption means both halves land on the same figure here by construction, not because that is guaranteed on every blend listing.

That even-split assumption is the weak point in any tesamorelin vs CJC-1295 ipamorelin price comparison built on a blend vial. A seller may not price the two peptides in a blend evenly — one compound may cost more to synthesize than the other — and a listing rarely discloses the internal cost breakdown. Without that disclosure, a per-compound figure pulled from a blend vial is an estimate, not a confirmed cost.

Why Tesamorelin Tends to Sit at a Different Per-Mg Figure

Even after normalizing to cost per mg, tesamorelin listings and CJC-1295/ipamorelin listings rarely converge on a shared number, for reasons independent of any single seller’s pricing choices:

• Molecular size and synthesis complexity. Tesamorelin is a larger peptide chain than either CJC-1295 or ipamorelin, and synthesis cost scales with chain length, which passes through to listed price.
• Blend vs single-compound packaging. A blend vial spreads fixed packaging and labeling costs across two compounds at once, which can lower the effective per-mg figure for each relative to a single-compound vial of similar total size.
• Typical vial size by category. Growth-hormone-releasing compounds sold as blends are frequently packaged in smaller total-mg vials than single-compound GHRH analogs, changing the fixed-cost share of the per-mg calculation.
• Testing and purity claims. As with any peptide listing, a stated third-party purity test tends to correlate with a different price tier, regardless of which compound or blend is being priced.

None of these factors make one listing’s per-mg figure incorrect relative to another. They describe why a tesamorelin vs CJC-1295 ipamorelin price comparison is comparing figures from different production and packaging models, not the same cost curve applied to three interchangeable peptides.

Reconstitution Concentration Is a Separate Calculation

Once any of these vials is reconstituted with bacteriostatic water, the resulting concentration is unrelated to what was paid for the vial: concentration = vial mg ÷ mL of water added. A 10 mg tesamorelin vial reconstituted with 2 mL of water yields 10 ÷ 2 = 5 mg/mL. A 10 mg CJC-1295/ipamorelin blend vial reconstituted with 2 mL of water also yields 10 ÷ 2 = 5 mg/mL, since the total labeled content is what drives that calculation, not the compound split inside it. Rechecking both: 10 divided by 2 is 5 in each case.

That shared 5 mg/mL figure does not mean the two vials cost the same per mg — it only means the dilution math is identical when the total mg and water volume are identical. Cost per mg and concentration per mL answer different questions and should not be substituted for each other. Readers working through either calculation can cross-check the arithmetic against a tool like peptcalc.com once a vial’s mg content and diluent volume are set.

A Consistent Way to Run This Comparison

The same checklist applies regardless of which compounds are being priced against each other:

1. Confirm whether the listing is a single compound or a blend, and pull the per-compound split if it is a blend.
2. Flag any blend listing that gives a total mg figure without a stated split — it cannot be reduced to a per-compound cost.
3. Divide each figure to cost per mg using its own labeled content before comparing tesamorelin against the blend or against ipamorelin alone.
4. Treat an even-split assumption on an undisclosed blend as an estimate, not a confirmed figure.

Sellers’ underlying reference material on heezresearch.com/product/tesamorelin/ documents the same vial-labeling conventions this per-mg calculation depends on, which is worth checking before assuming a tesamorelin listing and a blend listing are using the term “vial” or “mg” the same way. For readers tracking how tesamorelin-specific listings are worded and revised over time, peer tesamorelin listing catalogs follows how this compound’s per-vial and per-mg figures shift across sellers, which is useful context when a tesamorelin figure looks out of line with what a comparable blend listing shows.

Summary

A tesamorelin vs CJC-1295 ipamorelin price comparison depends first on identifying whether the non-tesamorelin listing is a single compound or a blend, since a blend vial’s total mg figure cannot be compared directly to tesamorelin’s single-compound mg figure without pulling out the per-compound split. Once each listing is reduced to cost per mg on its own terms, the comparison becomes a straightforward division problem — but any per-compound figure taken from an undisclosed blend split should be treated as an estimate rather than a confirmed cost.